An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: UCLA Health, UCLA Jonsson Comprehensive Cancer Center, Mayo Clinic, Baptist Hospital of Miami, Baptist Health South Florida, Northwest Medical Specialties, Los Alamitos Medical Center, Cleveland Clinic, Duke University, Rutgers, The State University of New Jersey, Moffitt Cancer Center, Saint Luke's Health System, Saint Luke's Hospital, Summit Medical Group (United States), Avera Health, Eisai (United States), University of California, San Francisco
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399324649